Tuesday, 29 April 2014

Blood Disease Treatment Drugs Market – Global Analysis and Industry Forecast, 2013-2019

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Sparkling Bottled Water Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure.

Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and blood cancers due to aging, infections, exposure to certain chemicals, smoking, genetic disorders and other factors. 


Hence, the category of blood disorders is wide and numerous types of diseases fall under it. There are three main types of cancer that affect blood namely leukemia which affects the bone marrow and is caused by abnormal production of white blood cells. Myeloma is a type of blood cancer that affects plasma cells whereas lymphoma is a cancer that affects the lymphatic system. The diseases that affect white blood cells are mainly lymphoma and leukemia and  anemia, sickle cell anemia and polycythemia diseases are mainly affecting red blood cells. Diseases such as heparin, thrombocytopenia and essential thrombocytosis affect the platelets found in blood and hemophilia and sepsis affect blood plasma. 

Hematological cancers represent a significant problem globally. Every year more than 100,000 cases of blood cancers are diagnosed in United States and more than 50,000 people die from such cancer cases. Many specific therapies for the treatment of cancers have been developed that include biologics and small-molecule drug therapies. Leukemia accounts for the ninth most common occurring cancer in males across the globe. Leukemia market is segmented into four types that include acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. Thus, with the rise in number of cancer cases the market in future is projected to grow. 

Drugs such as Sprycel, Arranon, Clolar, Gleevec, Quizartinib, Marqibo, and Tasigna are the major drugs available for the treatment of leukemia. The blood diseases treatment drugs market is witnessing competition among the players with drugs in pipeline for early diagnosis and treatment of blood disorders. 

Some of the key players in the blood disease treatment drugs market include Novartis International AG, Celgene Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals, Ambit Bioscience and other major players.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


About Us:-

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers. 

Contact Us 

Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States Tel: +1-518-618-1030

Browse Market Research Report:- 

Wednesday, 23 April 2014

Global Treatments For Neurodegenerative Disorders Market

Neurodegenerative disorders cause progressive loss of function structure of the neurons in the human brain. The most commonly known neurodegenerative diseases are Alzheimer’s, Parkinson’s, Amyotrophic lateral sclerosis, and Huntington’s Syndrome. Most neurodegenerative disorders are caused because of genetic mutation in completely unrelated cells.


Increase in the awareness regarding mental disorders and the rise in research and development regarding the treatment of such disorders are the major factors that are driving the growth of this market. However, despite large scale advancement in research in this field, there is a lack of complete curative treatment measures due to the manifold nature of the diseases. Moreover, many of the drugs presently available are for the treatment of symptoms of such diseases.

The market for neurodegenerative diseases can be categorized into major segments namely, progressive dementia, dementia with other neurological abnormalities and movement disorders. Out of these segments, the largest market share is occupied by progressive dementia followed by dementia with other neurological abnormalities. The major diseases segmented under neurodegenerative disorders are Huntington’s disease, Alzheimer’s disease, Pick’s disease, corticobasal ganglionic degeneration, Lewy body dementia, progressive supranuclear palsy, Hallervorden-Spatz disease, and multiple system atrophy.

Geographically, this market can be classified as North American, European, Asia Pacific, and the Rest of the World market. The major players in the neurodegenerative disorders market are Abbott Laboratories, Acorda Therapeutics, Inc., Baxter International, Inc., Boehringer Ingelheim Ltd., Cipla Ltd., Cellzome AG, Colucid Pharmaceuticals, Inc., Daiichi Sankyo Co. Ltd., Glenmark Generics Ltd., Neuro-Hitech, Inc., Roche Holding Ltd. and others.

This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


About Us:-

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

Contact Us
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030

Browse Market Research Report:-

Friday, 4 April 2014

Factor And Growrh Of Continuous Glucose Monitoring(CGM) Market 2013 - 2019

The global continuous glucose monitorin(CGM) market was valued at USD 0.37 billion in 2012 and is expected to grow at a CAGR of 13.6% from 2013 to 2019, to reach an estimated value of USD 0.91 billion in 2019.


Browse Global Sterilization Equipment and Disinfectants Market Report with Full TOC athttp://www.transparencymarketresearch.com/continuous-glucose-monitoring.html


Continuous glucose monitoring systems (CGMS) are real time glucose monitoring devices that measure and display the glucose level of the interstitial fluid in the skin cells of the patient. These devices help patients manage diabetes (Type 1 and Type 2) in a more efficient manner. CGM devices typically comprise a sensor, transmitter and a receiver. The sensor is placed underneath the skin for monitoring glucose levels and is attached to the transmitter that relays the information to the monitor. Until recently, management of diabetes involved the use of conventional blood glucose meters that provided a single time snapshot of the patient's blood glucose level. However, demand for real time monitoring, minimally invasive and effective diabetes management solutions led to the advent of CGM devices. Rise in the incidence of diabetes globally coupled with increasing awareness of such devices that possess the ability to detect hyper and hypoglycemic events in real time will fuel the growth of this market during the forecast period.



CGM is a rapidly evolving market supported by increasing adoption of these systems by hospitals and individual practitioners who further encourage their patients to use these devices. However, CGM systems are not meant to be replaced by the traditional diabetes management devices. Hence, the technology still requires innovation in terms of accuracy and precision. Reimbursement issues, high cost of devices and low market penetration rates are some of the factors that are expected to hinder market growth in the near future. Medtronic's Guardian Real Time CGM System accounted for the largest share of the global marketin 2012, accounting for a share of over 40%. The product's first mover advantage in the market, proper positioning and marketing of the product, and ease of convenience and usability helped it achieve this leadership position. Dexcom's fourth generation product, namely, Dexcom G4 Platinum is anticipated to witness the highest market growth at a CAGR of 22.6% during the forecast period. G4 Platinum is the most recently launched device (2012) and is the most technologically advanced, offering more accuracy and reliability as compared to other commercially available devices. In addition, integration of this device with insulin pumps from various other manufacturers like Johnson & Johnson and Tandem Diabetes Care would also drive the growth of this market segment.


Geographically, North America captured majority share of the global continuous glucose monitoring market in 2012. Increase in type I diabetic population along with rise in geriatric population which will in turn spur the demand for regular monitoring of glucose levels will fuel the growth of this market. Major players of this market are domiciled in this region, which allows easy market penetration and will also contribute towards market growth. The European CGM market is in a rapidly evolving state and contributed the largest share of the total CGM market revenue in 2012. Asia-Pacific is expected to witness tremendous increase its market share and emerge as the fastest growing region, reporting a CAGR of 16.9% during the forecast period. Economic developments, presence of a large patient pool, rising patient awareness, increasing disposable income and changing lifestyle are some of the significant factors that are poised to increase the demand for CGM systems in this region.


Key players in this market include Medtronic, Inc., Dexcom, Inc. and Abbott Diabetes Care. Medtronic was the leading player of this market in 2012, accounting for a share of over 50%. Abbott saw a decline in its market share due to withdrawal of Free Style Navigator from the U.S. market in the fourth quarter of 2011. However, the expected launch of Free Style Navigator ll in 2014 in the U.S. market would help the company restore its market position. Other companies such as Johnson & Johnson, Bayer Healthcare and Tandem Diabetes Care are adopting the strategy of partnerships and collaboration to enter this dynamic market.


The global continuous glucose monitoring market is segmented as follows:


Continuous Glucose Monitoring Market, by Device/Brand

  1. Guardian Real Time CGM System

  2. Dexcom Seven Plus

  3. Dexcom G4 Platinum

  4. FreeStyle Navigator

  5. MiniMed Paradigm Revel/Veo System

  6. Others


BrowseSterilizationEquipmentandDisinfectants Market athttp://www.transparencymarketresearch.com/continuous-glucose-monitoring.html


Continuous Glucose Monitoring Market, by Geography
  1. North America

  2. Europe

  3. Asia-Pacific

  4. Rest of the World (RoW)



Browse all Medical Devices Market Research Reports @http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html